Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company focused on tackling difficult-to-treat cancers and inflammation via precision macrophage immunotherapy, has appointed Faron co-founder Maija Hollmén, Ph.D., as chief scientific officer.   In her new role, Dr. Hollmén will oversee preclinical and support clinical development for Faron. Her priority will be the further development of bexmarilimab, Faron’s wholly owned, novel precision cancer immunotherapy candidate. Bexma...